Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?

Multiple sclerosis (MS) more than any other neurological disorder has experienced a tremendous progress in available evidence-based innovator disease modifying therapies (DMT). These medications include injectable complex nonbiological drugs (CNBD), the injectable biological products β-interferons-1...

Descripción completa

Detalles Bibliográficos
Autor principal: Rivera, Victor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858917/
https://www.ncbi.nlm.nih.gov/pubmed/31313222
http://dx.doi.org/10.1007/s40120-019-0145-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858917/
https://www.ncbi.nlm.nih.gov/pubmed/31313222
http://dx.doi.org/10.1007/s40120-019-0145-0

Ejemplares similares